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BACKGROUND: Data on the incidence of adverse liver outcomes are limited for cancer patients with chronic (hepatitis B surface anti-
gen [HBsAg]–positive/hepatitis B core antibody [anti-HBc]–positive) or past (HBsAg-negative/anti-HBc–positive) hepatitis B virus
(HBV) after chemotherapy. This study was aimed at determining the impact of test timing and anti-HBV therapy on adverse liver out-
comes in these patients. METHODS: Patients with solid or hematologic malignancies who received chemotherapy between 2004 and
2011 were retrospectively studied. HBV testing and anti-HBV therapy were defined as early at the initiation of cancer therapy and as
late after initiation. Outcomes included hepatitis flares, hepatic impairment, liver failure, and death. Time-to-event analysis was used
to determine incidence, and multivariate hazard models were used to determine predictors of outcomes. RESULTS: There were 18,688
study patients (80.4% with solid tumors). The prevalence of chronic HBV was 1.1% (52 of 4905), and the prevalence of past HBV was
7.1% (350 of 4905). Among patients with solid tumors, late identification of chronic HBV was associated with a higher risk of hepatitis
flare (hazard ratio [HR], 4.02; 95% confidence interval [CI], 1.26-12.86), hepatic impairment (HR, 8.48; 95% CI, 1.86-38.66), liver failure
(HR, 9.38; 95% CI, 1.50-58.86), and death (HR, 3.90; 95% CI, 1.19-12.83) in comparison with early identification. Among patients with
hematologic malignancies and chronic HBV, the risk of death was 7.8 (95% CI, 1.73-35.27) times higher for persons with late initiation
of anti-HBV therapy versus early initiation. Patients with late identification of chronic HBV had late or no anti-HBV therapy. Chronic
HBV predicted liver failure in patients with solid or hematologic malignancies, whereas male sex and late identification were predic-
tors for patients with solid tumors. CONCLUSIONS: Early identification correlates with early anti-HBV therapy and reduces the risk of
liver failure and death in chronic HBV patients receiving chemotherapy. Cancer 2017;123:3367-76. VC 2017 American Cancer Society.
KEYWORDS: antiviral therapy, cancer, hematologic malignancies, hepatitis B, hepatitis B reactivation, hepatitis B screening, hepatitis
flare, liver failure.
INTRODUCTION
Hepatitis B virus (HBV) affects nearly 2 billion people worldwide and can lead to serious liver diseases.1 The balance
between liver injury and viral control is regulated by the host immune system,2 and immunosuppressive therapies that dis-
rupt the immune balance can lead to reactivation of HBV replication and result in hepatitis flares, liver failure, and
death.3
For patients receiving anticancer therapy, HBV testing4-7 and anti-HBVmedications8,9 are recommended to prevent
HBV reactivation. However, uptake has been low,10 particularly for patients with solid tumors,11 and this may be in part
due to the lack of clinical outcome data to support an optimal management strategy. We conducted this retrospective
study to determine the impact of early HBV identification versus late identification and the impact of early initiation of
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anti-HBV therapy versus late/no initiation on the devel-
opment of adverse liver outcomes among patients with
chronic or past HBV infections receiving cancer therapy.
MATERIALS AND METHODS
We assembled a retrospective cohort of patients aged 18
years or older with solid or hematologic malignancies who
presented to The University of Texas MD Anderson Can-
cer Center and received the first outpatient administration
of parenteral cancer therapy between 2004 and 2011. We
excluded patients with hepatocellular carcinoma because
they would be more likely to be screened for HBV and to
be treated with anti-HBV therapy if they tested positive.
Furthermore, hepatitis flares and liver failure in these
patients may be due to underlying liver disease and not to
cancer treatment. Demographic and clinical characteris-
tics were obtained from institutional databases. This study
was conducted after approval by our institutional review
board.
A chronic HBV infection was defined as hepatitis B
surface antigen (HBsAg)–positive/hepatitis B core anti-
body (anti-HBc)–positive or HBsAg–positive/anti-HBc–
unknown. A past HBV infection was defined as HBsAg-
negative/anti-HBc–positive or HBsAg-unknown/anti-
HBc–positive, regardless of the hepatitis B surface anti-
body status.
The chemotherapy initiation period was defined as
the period from 2 months before the first administration
of chemotherapy until the beginning of the second
chemotherapy cycle (Fig. 1). The postchemotherapy
initiation period was defined as the period from the begin-
ning of the second chemotherapy cycle to the end of the
study period. We defined early HBV identification as 1 or
more of the following: HBsAg or anti-HBc tests at MD
Anderson during the chemotherapy initiation period,
known positive HBsAg or anti-HBc tests, and anti-HBV
therapy before first chemotherapy. Late HBV identifica-
tion was defined as HBsAg and/or anti-HBc tests at MD
Anderson after the chemotherapy initiation period. Early
initiation refers to anti-HBV medications started before
or during the chemotherapy initiation period and before
any adverse liver outcome; late initiation refers to medica-
tions started after the chemotherapy initiation period
before or after an adverse liver outcome.
We identified outcomes between the administration
of the second cycle of chemotherapy and 2 years after the
last chemotherapy administration at MD Anderson, last
follow-up, or death (Fig. 1). We defined a hepatitis flare as
an alanine aminotransferase level  100 U/L that was also
3 times the baseline alanine aminotransferase level in the
chemotherapy initiation period.12 Hepatitis impairment
was defined as a hepatitis flare and either a total bilirubin
level  2.5 mg/dL or an international normalized ratio 
1.5. Liver failure was defined as a hepatitis flare and either
ascites or encephalopathy as determined from claims using
International Classification of Diseases, Ninth Revision codes.
All-cause mortality was determined through our tumor reg-
istry. HBV DNA testing was not performed for all HBV
patients; thus, we could not determine HBV reactivation as
an outcome.
Figure 1. Timeline of the study periods. Chemotherapy initiation occurred from 2 months before the first chemotherapy adminis-
tration until the administration of the second cycle of chemotherapy. Postchemotherapy initiation occurred after the administra-
tion of the second cycle of chemotherapy until the end of the study period (2011). Early HBV identification was defined as
positive findings on HBsAg or anti-HBc tests performed before or during the chemotherapy initiation period or anti-HBV therapy
before first chemotherapy. Late HBV identification was defined as positive findings on HBsAg or anti-HBc tests performed after
the chemotherapy initiation period. Early anti-HBV therapy initiation was defined as HBV medication started before or during the
chemotherapy initiation period and before any adverse liver outcome. Late anti-HBV therapy initiation was defined as HBV medi-
cation started after chemotherapy initiation and before or after any adverse liver outcome. Outcomes occurred from the adminis-
tration of the second cycle of chemotherapy up to 2 years after the last chemotherapy administration at The University of Texas
MD Anderson Cancer Center, the last follow-up, or death. Anti-HBc indicates hepatitis B core antibody; HBsAg, hepatitis B sur-
face antigen; HBV, hepatitis B virus.
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We used descriptive statistics and chi-square tests to
analyze characteristics of the study cohort. Time-to-event
analysis was used to compare liver-related outcomes
among patients by HBV status and by the timing of HBV
testing or anti-HBV therapy. Patients without outcomes
were censored at the last follow-up date, the date of death,
or 2 years after the last chemotherapy administration,
whichever came first. Those who experienced outcomes
more than 2 years after the last chemotherapy administra-
tion were censored at 2 years. Competing risk analysis for
the hazard of outcomes was performed to account for
competing risks of death for those who died without liver
outcomes. To compare the likelihood of liver outcomes
between groups, we estimated the cumulative incidence
function and hazard ratios (HRs) for the liver failure sub-
distribution with the Fine-Gray model.13 Multivariate
subdistribution hazard models were developed to sepa-
rately determine predictors of liver failure among HBV
patients with solid tumors or hematologic malignancies.
Covariates included demographics, the HBV status, and
the timing of HBV identification and anti-HBV therapy.
Rituximab administration and stem cell transplantation,
treated as time-varying covariates, were also included for
patients with hematologic malignancies. The model selec-
tion implemented stepwise methods by which the P value
for entry was .10 and the P value to remain was .05.
Because of the strong correlation between the timing of
HBV identification and the timing of the initiation of
anti-HBV therapy, we explored multivariate models in
which either one of the two was excluded.
RESULTS
A total of 18,688 patients received chemotherapy during
the study period, and 80.4% (n 5 15,031) had solid
tumors, whereas 19.6% (n 5 3657) had hematologic
malignancies (Table 1). Overall, 19.9% had early HBV
testing, 6.3% had late testing, and 73.8% were not tested.
Among the 4905 tested patients, the overall prevalence of
chronic HBV infection was 1.1% (n5 52), and the over-
all prevalence of past HBV infection was 7.1% (n5 350).
Patients with hematologic malignancies had higher rates
of HBV testing (89.6% [n 5 3277]), most of which
occurred early (90.5%, n 5 2965), in comparison with
patients with solid tumors (overall testing, 10.8% [n 5
1628]; early testing, 46.4% [n 5 756]). There were high
rates of HBV testing among patients who received rituxi-
mab (88.9% [1602 of 1803]), allogeneic stem cell trans-
plantation (100% [479 of 479]), or autologous stem cell
transplantation (99.4% [709 of 713]).
The prevalence among patients with hematologic
malignancies was 0.8% for chronic HBV (25 of 3277)
and 6.0% (196 of 3277) for past HBV. The prevalence
among patients with solid tumors was 1.7% (27 of 1628)
for chronic HBV and 9.5% (154 of 1628) for past HBV.
Among Asian and black patients with solid tumors, the
prevalence was 11.8% and 2.1% for chronic infection and
34.2% and 12.2% for past infection, respectively.
Twenty-six of 52 chronic HBV patients had serum HBV
DNA testing (median, 16 days after HBV identification;
range, 2 days to 7 months); 12 had undetectable HBV
DNA, and 14 had detectable HBV DNA (median,
49,350 IU/mL; range, 1930-50,000,000 IU/mL).
The median follow-up duration for the study cohort
was 26 months (range, 2 days to 88.6 months). The inci-
dence of each liver outcome was higher for chronic or past
HBV patients versus HBV-negative patients and for
patients with late HBV identification versus those with
early HBV identification and was lowest for the untested
patients (Table 2). The incidence of liver failure for
patients with solid or hematologic tumors was 11.7%
when the HBV infection was diagnosed late, 7.4% when
the HBV infection was diagnosed early, and 7.8% with-
out an HBV infection (Table 2). Of the patients with a
chronic or past HBV infection and liver failure, 53% (n5
18) developed liver failure while receiving chemotherapy,
and 47% (n 5 16) developed liver failure after the last
chemotherapy cycle.
Among patients with solid tumors, late identifica-
tion of chronic HBV was significantly associated with a
higher risk of hepatitis flare (hazard ratio [HR], 4.02;
95% confidence interval [CI], 1.26-12.86), hepatic
impairment (HR, 8.48; 95%CI, 1.86-38.66), liver failure
(HR, 9.38; 95% CI, 1.50-58.86), and death (HR, 3.90;
95% CI, 1.19-12.83) in comparison with early identifica-
tion (Table 3). Among the 181 patients with solid tumors
and chronic or past HBV infections, 15 patients had liver
failure. Of these, 6 had colorectal cancer, 3 had other gas-
trointestinal cancers (esophageal cancer [n 5 1], stomach
cancer [n 5 1], and pancreatic cancer [n 5 1]), 2 had
breast cancer, 2 had lung cancer, 1 had melanoma, and 1
had thymoma. Figure 2 shows a significantly higher
cumulative incidence of liver failure for solid tumor
patients with late identification of chronic HBV versus
early identification. For patients with hematologic malig-
nancies, we could not fully evaluate the effect of the tim-
ing of chronic HBV identification on liver impairment or
liver failure because of the small numbers of patients with
late identification.
Liver Outcomes for HBV Cancer Patients/Hwang et al
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There was no significant association between the
timing of anti-HBV therapy and liver failure (Table 4).
However, we found that the timing of HBV identification
and the timing of anti-HBV therapy were highly correlat-
ed: among the 39 chronic HBV patients who had early
testing, 23 started anti-HBV therapy before or at the initi-
ation of cancer therapy, whereas all 13 chronic HBV
patients who had late identification had late/no anti-HBV
therapy. Among patients with hematologic malignancies,
the risk of a hepatitis flare (HR, 3.13; 95% CI, 1.24-7.92)
or hepatic impairment (HR, 5.09; 95% CI, 1.19-21.74)
for past HBV patients and the risk of death for chronic
HBV patients (HR, 7.82; 95% CI, 1.73-35.27) were sig-
nificantly higher for persons with late anti-HBV therapy
initiation in comparison with those with early anti-HBV
therapy initiation (Table 4). Among patients who received
rituximab, all 12 with chronic HBV and 31 of 103 with
past HBV had early initiation of anti-HBV therapy. For
patients with solid tumors, we could not fully evaluate the
effect of the timing of anti-HBV therapy on liver failure
because of the small numbers of patients.
Among patients with solid tumors, those with
chronic HBV had a higher risk of liver failure than those
with past HBV (HR, 4.94; 95% CI, 1.82-13.45), and
those with late identification of an HBV infection had a
higher risk of liver failure than those with early identifica-
tion (HR, 2.86; 95% CI, 0.99-8.24; Table 5). Male sex
was also a predictor of liver failure among solid tumor
patients. For patients with hematologic malignancies,
chronic HBV was a predictor of liver failure (HR, 3.34;
95%CI, 1.10-10.17; Table 5).
DISCUSSION
In this analysis of a large cohort of patients receiving anti-
cancer therapy, we found that late identification of chron-
ic HBV after chemotherapy initiation for solid tumors led
to higher risks of adverse liver outcomes in comparison
with early HBV detection. We also found that late or no
anti-HBV therapy was associated with higher rates of
mortality than early anti-HBV therapy for chronic HBV
patients with hematologic malignancies. The timing of
the identification of an HBV infection was correlated
with the timing of anti-HBV therapy, and this suggests
that the benefits of early HBV identification could be
related to the early use of anti-HBV therapy or to close
monitoring and early anti-HBV treatment at the first sign
of a hepatitis flare.
Among the more than 15,000 patients in our study
who had solid tumors, a chronic HBV infection and the
late identification of a chronic or past HBV infection were
independent risk factors for liver failure. The late identifi-
cation of a chronic HBV infection was also associated
with higher rates of hepatitis flare, hepatic impairment,
and all-cause mortality. Previous studies have not exam-
ined the impact of early testing versus late testing on
adverse liver outcomes in patients with solid tumors. In
one study in which breast, colon, or lung cancer patients
were screened before chemotherapy, there were no cases
of liver failure among 30 patients with a chronic HBV
infection with early HBV testing, of whom 28 had under-
gone early anti-HBV therapy.14 In contrast, the rate of liv-
er failure in our study was 6.7% for solid tumor patients
with chronic HBV, and it was likely higher because none
had early anti-HBV therapy.
Among patients with hematologic malignancies who
had HBV testing, more than 90% were tested early.
Because of the low numbers for late testing, we did not
observe any difference in outcomes between patients with
early HBV infection identification and patients with late
identification. However, we found a 7.82 (95% CI, 1.73-
35.27) times higher risk of death for chronic HBV
patients with late/no anti-HBV therapy in comparison
with those with early therapy. Data from randomized clin-
ical trials have supported the benefit of early anti-HBV
therapy among patients with hematologic malignancies.
In one study of 30 lymphoma patients with chronic HBV,
0 of 15 patients in the prophylaxis group and 1 of 15 in
the group that was closely monitored with anti-HBV
medication initiated upon an HBV DNA elevation
died.15 In our study, the mortality rate was higher, 3 of 17
in the early anti-HBV therapy group and 6 of 8 in the
late/no anti-HBV therapy group, likely because of less
Figure 2. Cumulative incidence of liver failure in chronic HBV
patients with solid tumors by the timing of HBV identifica-
tion. HBV indicates hepatitis B virus.
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rigorous monitoring and delays in starting anti-HBV
treatment.
The strengths of our study include a large cohort of
patients with different tumor types providing much needed
information on HBV reactivation in patients with solid
tumors in a country with a lowHBV prevalence. The major
limitation is the retrospective design, which limited our abil-
ity to ascertain whether patients meeting our criteria for liver
failure truly had liver failure, to identify the exact etiology of
adverse liver outcomes, and to assess adherence to anti-HBV
therapy. We were unable to determine the effects of specific
chemotherapy on adverse liver outcomes because many
patients received more than 1 chemotherapy drug simulta-
neously or changed treatment regimens over time. Also,
HBV DNA testing was not routinely performed, and thus
liver outcomes could not be attributed to HBV reactivation.
In addition, baseline hepatitis B e antigen and HBV DNA
testing was not performed for all patients with a chronic
HBV infection, and this limited the impact of the chronic
HBV phase on the risk of adverse liver outcomes. Finally,
our study represents practice patterns of a single institution,
and the findings may not be representative.
In summary, our study demonstrated that among
chronic HBV patients, early identification reduced the risk
of liver failure for patients with solid tumors, and early anti-
HBV therapy reduced all-cause mortality for patients with
hematologic malignancies. Alerts in electronic health systems
could facilitate HBV screening and early anti-HBV thera-
py.16,17 Future efforts should focus on the risk of HBV reac-
tivation and optimal strategies for HBV screening and
prophylactic antivirals in patients with solid tumors.
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